6th International AIDS Conference


San Francisco, California, USA — June 20-23, 1990

Print this Article


Integration of HIV-I CD4-binding region in different sites of p55 core protein as a possible vaccine candidate.

Int Conf AIDS 1990 Jun 20-23; 6:328 (abstract no. 1059)
Fliessbach H, Wagner R, Deby G, Modrow S, von Brunn A, Wolf H; Max von Pettenkofer Institut, Munchen, FRG

OBJECTIVE: Conventional strategies for HIV vaccine development based on a vaccine against the membrane protein gp120/160 seemed not to be successful. Furthermore immunisation with gp120/160 resulted in the formation of enhancing antibodies. The p55 gag protein of HIV-I should be an appropriate candidate for a HIV-I vaccine due to its early appearance in HIV-I infection. Core particles have been shown in other virus systems to be highly immunogenic (Hepatitis). In our approach we used core particles as an autologous carrier for the CD4-binding region of the gp120 envelope protein.

METHODS: The CD4-binding region was inserted in different sites of the p55 core protein precursor. The expression of resulting gag/env fusion proteins in E. coli, Vaccinia and Baculo was investigated in Western blot analysis and immune fluorescence. The formation of the gag/env particles will be examined with sedimentation analysis and electronmicroscopy.

RESULTS: Western blot analysis and immune fluorescence showed expression of the gag/env fusion proteins in E. coli, Vaccinia- and Baculo virus systems. Particle formation of the recombinant proteins is studied by immune electronmicroscopy, further characterisation of immunogenicity will be presented by using the particles produced in the various systems for inoculation in experimental animals.

CONCLUSIONS: The possibility to form immunogenic particles, which stimulate the immune reaction not only to the HIV-I core proteins, but also to the inserted CD4-binding region, will be evaluated by the appearance of specific antibodies and T-cell proliferation. The recombinant vaccinia viruses will be used as a vaccine for immunisation of experimental animals and for antigen production in lytically infected cells.

Keywords: AEGIS, Antigens, CD4, HIV, Gene Products, gag, AIDS Vaccines, Gene Products, env, Bacterial Proteins, HIV Antigens, HIV Antibodies, Vaccinia virus, Protein Precursors, Escherichia coli, Recombinant Proteins, P55 protein, ICA6KWDaegis,antigens,cd4,hiv,geneproducts,gag,aidsvaccines,geneproducts,env,bacterialproteins,hivantigens,hivantibodies,vacciniavirus,proteinprecursors,escherichiacoli,recombinantproteins,p55protein,ica6

900620
1059

Copyright © 1990 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.